When you hear the words Alzheimer's disease, what do you think of? The truth is, the picture most of us have of the disease is incomplete. Alzheimer's disease doesn't start when someone starts to lose their memory. It actually starts years – sometimes decades – earlier. The Rethinking Alzheimer's Disease Podcast is an engaging, narrative-style podcast miniseries for those curious or motivated to learn about Alzheimer’s disease. Perhaps you have a family member with Alzheimer’s disease, or ca ...
…
continue reading
Content provided by Audioboom and MJH Life Sciences. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and MJH Life Sciences or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Redefining Response in mHSPC: Ultralow PSA, Treatment Nuance, and the Call for More Equitable Care
MP3•Episode home
Manage episode 509699193 series 3310604
Content provided by Audioboom and MJH Life Sciences. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and MJH Life Sciences or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Jack R. Andrews, MD; Alicia Morgans, MD, MPH; and Murilo de Almeida Luz, MD, discuss how ultralow prostate-specific antigen thresholds (below 0.02) serve as important prognostic biomarkers in metastatic hormone-sensitive prostate cancer, with recent post hoc analyses from the ARANOTE trial showing that patients achieving these ultralow levels with combination androgen deprivation therapy plus darolutamide therapy have significantly better radiographic progression-free survival and time to castration-resistant disease compared with those who don't reach these thresholds.
92 episodes
MP3•Episode home
Manage episode 509699193 series 3310604
Content provided by Audioboom and MJH Life Sciences. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and MJH Life Sciences or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Jack R. Andrews, MD; Alicia Morgans, MD, MPH; and Murilo de Almeida Luz, MD, discuss how ultralow prostate-specific antigen thresholds (below 0.02) serve as important prognostic biomarkers in metastatic hormone-sensitive prostate cancer, with recent post hoc analyses from the ARANOTE trial showing that patients achieving these ultralow levels with combination androgen deprivation therapy plus darolutamide therapy have significantly better radiographic progression-free survival and time to castration-resistant disease compared with those who don't reach these thresholds.
92 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.